• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Estimating the duration of ongoing prevention trials.

作者信息

Church T R, Ederer F, Mandel J S, Watt G D, Geisser M S

机构信息

Division of Environmental and Occupational Health, School of Public Health, University of Minnesota, Minneapolis 55414.

出版信息

Am J Epidemiol. 1993 Apr 1;137(7):797-810. doi: 10.1093/oxfordjournals.aje.a116740.

DOI:10.1093/oxfordjournals.aje.a116740
PMID:8484371
Abstract

The authors present a method of estimating the duration of ongoing prevention trials, showing how the method was applied to the Colon Cancer Control Study, a University of Minnesota study of occult blood testing undertaken to screen for colorectal cancer in older Minnesotans. In that study, begun in 1975 and ongoing, as in several other recent large prevention trials, it was necessary, after the start of the study, to revise upward the initial estimates of study duration derived from general population experience. The underestimates arose because the planners had not adequately taken various population selection factors into account in estimating the expected number of events in the control group. In this paper, the authors outline a method for estimating control group event rates and study duration requirements (and, in some circumstances, also sample size requirements) of prevention studies, via models of disease-specific and all-cause standardized mortality ratios which adjust for various selection effects. The authors also validate the model for disease-specific standardized mortality ratios by means of independent estimates of disease incidence and case survival.

摘要

相似文献

1
Estimating the duration of ongoing prevention trials.
Am J Epidemiol. 1993 Apr 1;137(7):797-810. doi: 10.1093/oxfordjournals.aje.a116740.
2
Sample sizes for prevention trials have been too small.
Am J Epidemiol. 1993 Apr 1;137(7):787-96. doi: 10.1093/oxfordjournals.aje.a116739.
3
Fecal occult blood screening in the Minnesota study: role of chance detection of lesions.
J Natl Cancer Inst. 1997 Oct 1;89(19):1423-8. doi: 10.1093/jnci/89.19.1423.
4
5
Fecal occult blood screening in the Minnesota study: sensitivity of the screening test.明尼苏达研究中的粪便潜血筛查:筛查试验的敏感性
J Natl Cancer Inst. 1997 Oct 1;89(19):1440-8. doi: 10.1093/jnci/89.19.1440.
6
Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial.前列腺、肺、结肠直肠癌和卵巢癌筛查试验中健康志愿者效应的证据。
Am J Epidemiol. 2007 Apr 15;165(8):874-81. doi: 10.1093/aje/kwk075. Epub 2007 Jan 22.
7
Aspirin and other nonsteroidal anti-inflammatory agents in the prevention of colorectal cancer.阿司匹林及其他非甾体抗炎药在结直肠癌预防中的应用
Important Adv Oncol. 1996:123-37.
8
Correcting for misclassification and selection effects in estimating net survival in clinical trials.校正临床试验中净生存估计的分类错误和选择效应。
BMC Med Res Methodol. 2019 May 16;19(1):104. doi: 10.1186/s12874-019-0747-3.
9
Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy.采用粪便潜血试验和乙状结肠镜检查筛查结直肠癌。
J Natl Cancer Inst. 1993 Aug 18;85(16):1311-8. doi: 10.1093/jnci/85.16.1311.
10
Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study.通过粪便潜血筛查降低结直肠癌死亡率。明尼苏达结肠癌控制研究。
N Engl J Med. 1993 May 13;328(19):1365-71. doi: 10.1056/NEJM199305133281901.

引用本文的文献

1
Insights from UKCTOCS for design, conduct and analyses of large randomised controlled trials.英国癌症研究中心临床试验(UKCTOCS)对大型随机对照试验的设计、实施及分析的见解。
Health Technol Assess. 2023 Aug;29(10):1-48. doi: 10.3310/CLDC7214.
2
Impact on mortality and cancer incidence rates of using random invitation from population registers for recruitment to trials.随机抽取人群登记册进行试验招募对死亡率和癌症发病率的影响。
Trials. 2011 Mar 1;12:61. doi: 10.1186/1745-6215-12-61.
3
Cancer screening trials: nuts and bolts.癌症筛查试验:要点解析。
Semin Oncol. 2010 Jun;37(3):216-23. doi: 10.1053/j.seminoncol.2010.05.009.
4
Principles of cancer screening: lessons from history and study design issues.癌症筛查原则:从历史和研究设计问题中吸取的教训。
Semin Oncol. 2010 Jun;37(3):202-15. doi: 10.1053/j.seminoncol.2010.05.006.
5
Sample size matters: a guide for surgeons.样本量很重要:给外科医生的指南。
World J Surg. 2005 May;29(5):601-5. doi: 10.1007/s00268-005-7921-y.